Supplementary Figures 1 through 4 from Overcoming the Immunosuppressive Tumor Microenvironment of Hodgkin Lymphoma Using Chimeric Antigen Receptor T Cells
Year: 2023
Type: supplementary-materials
Abstract: Figure S1. CD123 and CD30 expression in Hodgkin lymphoma. Figure S2. Hodgkin Lymphoma polarizes normal macrophage to an immunosuppressive phenotype. Figure S3. Anti-lymphoma activity of CART123. Figure S4. CART123 efficiently kill macrophages.
Authors: Marco Ruella, Michael Klichinsky, Saad S. Kenderian, Olga Shestova, Amy Ziober, Daniel O. Kraft, Michael Feldman, Mariusz A. Wasik, Carl H. June, Saar Gill
Institutions: Abramson Cancer Center, University of Pennsylvania, Mayo Clinic
Language: English
Topic: CAR-T cell therapy research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4362531711